Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)

China flag China · Delayed Price · Currency is CNY
18.64
-1.21 (-6.10%)
At close: Jan 27, 2026
-23.32%
Market Cap44.62B
Revenue (ttm)10.91B -70.1%
Net Income-1.31B
EPS-0.55
Shares Out2.39B
PE Ration/a
Forward PE12.96
Dividend0.20 (1.01%)
Ex-Dividend DateDec 25, 2024
Volume83,369,150
Average Volume34,964,429
Open19.24
Previous Close19.85
Day's Range18.02 - 19.27
52-Week Range16.75 - 27.80
Beta0.77
RSI48.07
Earnings DateApr 28, 2026

About SHE:300122

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysacchar... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 7,220
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300122
Full Company Profile

Financial Performance

In 2024, SHE:300122's revenue was 26.07 billion, a decrease of -50.74% compared to the previous year's 52.92 billion. Earnings were 2.02 billion, a decrease of -74.99%.

Financial Statements